The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF in Sweden
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age of Participants at Disease Diagnosis
Timeframe: At disease diagnosis within 11 years before the study start date (Day 1)
Age of Participants at Start of Treatment With Benefix or Refacto
Timeframe: At start of treatment with Benefix/Refacto within 11 years before the study start date (Day 1)
Age of Participants at Start of Replacement Treatment
Timeframe: At start of replacement treatment within 11 years before the study start date (Day 1)
Average Prescribed Dose Per Infusion for Factor VIII and Factor IX Concentrates
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Prescribed Dose Per Kilogram Bodyweight for Factor VIII and Factor IX Concentrates
Timeframe: For the duration of 11 years before the study start date (Day 1)
Percentage of Participants on Prophylactic Treatment
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Prescribed Frequency of Infusions Per Week Dispensed for Haemophilia A or B Participants With Prophylaxis
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Prescribed Annual Dose of Factor VIII and IX Concentrates for Participants on Prophylaxis
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Prescribed Annual Dose of Factor VIII and IX Concentrates Per Kilogram Bodyweight for Participants on Prophylaxis
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Annual Registered Consumption of Factor VIII and IX Concentrates
Timeframe: For the duration of 11 years before the study start date (Day 1)
Number of Participants With Consumption of Factor VIII, Factor IX, Factor rVIIa and/or aPCC Concentrate
Timeframe: For the duration of 11 years before the study start date (Day 1)
Percentage of Time on Refacto or Benefix
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Use of Factor Concentrate Per Surgery Event at Hospital for Invasive Procedures
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Factor Concentrate Use at Hospital for Invasive Procedures
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Annual Number of Filled Prescriptions of Factor Concentrate
Timeframe: For a duration of 3 years (for up to 11 years before the study start Day 1)
Average Annual Number of Dispensed Units of Factor Concentrate
Timeframe: For a duration of 3 years (for up to 11 years before the study start Day 1)
Average Number of Units of Benefix or Refacto
Timeframe: For the duration of 11 years before the study start date (Day 1)
Total Number of Bleeds
Timeframe: For the duration of 11 years before the study start date (Day 1)
Number of Joint Bleed, Muscle Bleeds and Other Bleed Events in Participants
Timeframe: For the duration of 11 years before the study start date (Day 1)
Gilbert Joint Score
Timeframe: Data analyzed on study start Day 1 for the duration of 4 years (2005 to 2009)
Haemophilia Joint Health Score
Timeframe: Data analyzed on study start Day 1 for the duration of 6 years (2009 to 2015)
Percentage of Participants With Surgeries
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Relative Dose Intensity of Factor Concentrate Dispensed for Haemophilia A or B Participants on Prophylaxis Based on Dispensed Volume of Units
Timeframe: For the duration of 11 years before the study start date (Day 1)
Average Cost of Replacement Treatment (Benefix or Refacto/Refacto AF) Related to Bleed Event
Timeframe: For the duration of 11 years before the study start date (Day 1)